INS and type 2 diabetes mellitus: In a pooled analysis of 22 randomized controlled trials of patients with T2DM initiating basal insulin (insulin glargine or insulin detemir), the mean HbA1c reduction at endpoint was 1.4% (15 mmol/mol) and insulin dose ranged from 23 to 71 units.43